Aging induces a decrease in bone mass, and osteoporosis with its accompanying decrease in bone mass is widely recognized as a major public health problem. Bone loss with increasing age may be due to decreased bone formation and increased bone resorption. Pharmacologic and nutritional factors may prevent bone loss with aging, although chemical compounds in food and plants which act on bone metabolism are poorly understood. We have found that iso‰avones (including genistein and daidzein), which are contained in soybeans, have a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on osteoclastic bone resorption, thereby increasing bone mass. Menaquinone-7, an analogue of vitamin K 2 which is abundant in fermented soybeans, has been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption. Of various carotenoids, b-cryptoxanthin, which is abundant in Satsuma mandarin (Citrus unchiu MARC), has a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on osteoclastic bone resorption. The supplementation of these factors has a preventive eŠect on bone loss induced by ovariectomy in rats, which are an animal model of osteoporosis, and their intake has been shown to have a stimulatory eŠect on bone mass in humans. Factors with an anabolic eŠect on bone metabolism were found in extracts obtained from wasabi leafstalk (Wasabi japonica MATSUM), the marine alga Sargassum horneri, and bee pollen Cistus ladaniferus. Phytocomponent p-hydroxycinnamic acid was also found to have an anabolic eŠect on bone metabolism. Food chemical factors thus play a role in bone health and may be important in the prevention of bone loss with increasing age.
INTRODUCTION
Aging induces a decrease in bone mass. Osteoporosis with its accompanying decrease in bone mass is widely recognized as a major public health problem. The most dramatic expression of the disease is represented by fractures of the proximal femur, the number of which increases as the population ages. [1] [2] [3] [4] [5] Malnutrition or undernutrition is often observed in the elderly, and it appears to be more severe in patients with hip fracture than in the general aging population. 6, 7) Deˆciency in both micronutrients and macronutrients appears to be strongly implicated in the pathogenesis and the consequences of hip fracture in the osteoporotic elderly. 8) Nutritional and pharmacologic factors are important in preventing bone loss with increasing age.
Chemical compounds in food and plants which act on bone metabolism have not been fully clariˆed. Recent studies have shown that iso‰avones, which are contained in soybeans, menaquinone-7 (vitamin K 2 ), which is abundant in fermented soybeans, and bcryptoxanthin, which is present in fruit and vegetables, have been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption in vitro. The supplementation of iso‰a-vones, menaquinone-7, and b-cryptoxanthin has preventive eŠects on bone loss induced by ovariectomy in rats, which is an animal model of osteoporosis, and their intake has a stimulatory eŠect on bone mass in humans. Food chemical factors thus play a role in bone health and may be important in the prevention of bone loss with aging.
This review mainly describes ourˆndings concerning the biochemical action of food factors on bone metabolism and their preventive eŠects on osteoporosis.
ISOFLAVONE AND BONE METABOLISM
Iso‰avones including daidzin, daidzein, genistin, and genistein are present in soybeans at relatively high concentrations. As shown in Fig. 1 , daidzin and genistin are hydrolyzed to daidzein and genistein by b-glucosidase in the gastrointestinal system, respectively. Genistein has been shown to have a strong inhibitory eŠect on protein tyrosine kinase and it can cause cell cycle arrest and apoptosis in leukemic cells. Such a cellular mechanism may be important in the prevention of cancers. We demonstrated that genistein and daidzein have an anabolic eŠect on bone metabolism in rats, suggesting their role in the prevention of osteoporosis, which is widely recognized as a major public health problem. Iso‰avone as a food factor is useful in the prevention of and therapy for osteoporosis.
Action of Iso‰avone on Bone Formation in Tissue Culture
Bone metabolism is regulated by osteoblasts and osteoclasts localized in bone tissues. Osteoblasts stimulate bone formation and calciˆcation, while osteoclasts promote bone resorption. The anabolic eŠects of genistein on bone metabolism have been investigated in tissue culture using the femoralmetaphyseal (trabecular bone) tissues obtained from elderly female rats in vitro. 9, 10) Bone tissues were cultured for 24 h in Dulbecco's modiˆed Eagle's medium (MEM) (high glucose, 4.5 ％) with bovine serum albumin (serum free) and antibiotics containing either vehicle or genistein. The presence of genistein (10 -6 or 10 -5 M) was found to induce a signiˆcant increase in calcium content, alkaline phosphatase activity, which is a marker enzyme of osteoblasts, and DNA content, which is an index of bone cell number in bone tissues, in rat femoralmetaphyseal (trabecular bone) tissues. 9) The eŠects of genistein in increasing bone components were equal to the stimulatory eŠects of 17b-estradiol, which is physiologically important. Anti-estrogen agent tamoxifen was shown to inhibit completely the genistein-induced increase in bone components, although tamoxifen itself had no eŠect on bone components. 9) The anabolic eŠects of genistein on bone metabolism may be partly mediated through estrogen-like action. Presumably, genistein binds to the receptor of estrogen in osteoblastic cells in which this receptor is localized. 11, 12) The eŠects of genistein or genistin on bone components were compared in an in vitro culture system. 10) Culture with genistein (10 -8 -10 -5 M) or genistin (10 -7 -10 -5 M) was shown to increase alkaline phosphatase activity and DNA and calcium contents in the femoral-metaphyseal tissues obtained from elderly female rats. 10) The eŠects of genistein or genistin in increasing bone components were completely blocked in the presence of cycloheximide (10 -6 M), an inhibitor of protein synthesis in the translational process, suggesting that the anabolic eŠects of either iso‰a-vone are partly based on newly synthesized protein components.
The eŠects of daidzein on the femoral-diaphyseal (cortical bone) tissues obtained from elderly female rats in vitro were also investigated. 13) The presence of daidzein (10 -6 -10 -5 M) in culture medium caused a signiˆcant increase in bone components. This eŠect was equal to that of genistein (10 -6 or 10 -5 M). The combination of daidzein and genistein did not have an additive eŠect. In addition, the stimulatory eŠect of daidzein on bone components was completely suppressed in the presence of cycloheximide. Genistein is a 5, 7, 4′ -trihydroxyiso‰avone, and daidzein is a 7,4-dihydroxyiso‰avone, and the chemical structure of the two compounds is similar. Presumably, the chemical form of dihydroxyiso‰avone is important in its anabolic eŠects on bone. Genistein and daidzein may have a bone eŠect that operates via the same mechanism.
The eŠects of phosphogenistein and phosphodaidzein, which are phosphorylated for the hydroxyl group (OH) at the 7-position of genistein and daidzein, on bone components have been demonstrated. 14) Phosphogenistein or phosphodaidzein increases bone components in tissue culture in vitro. Phosphoiso‰avones at a lower concentration of 10
M, at which genistein and daidzein have anabolic eŠects on bone components, had no eŠect.
The eŠects of various polyphenols found in food and plants on bone metabolism have been determined. Glycitein, resveratol, quercetin, catechin, and (-)-epigallocatechin gallate do not have anabolic eŠects on bone calciˆcation in vitro. 15) Polyphenols do not directly stimulate bone calciˆcation in vitro. Genistein has unique anabolic eŠects on bone.
Genistein is a 4′ , 5, 7-trihydroxyiso‰avone, and daidzein is a 4′ , 7-dihydroxyiso‰avone. Glycitein is a 4′ , 7-dihydroxy-6-methoxy‰avone, while quercetin is a 3,3′ ,4′ ,5,7-pontahydeoxy‰avone; neither has any eŠect on bone calciˆcation in vitro. The anabolic eŠect of genistein and daidzen on bone calciˆcation is weakened by the phosphorylation of the hydroxygroup at their-7-position. 14) The hydroxy-groups at the 5-and 7-positions of the iso‰avone genistein may be necessary for its anabolic eŠect on bone formation, suggesting a chemical structure-activity relationship.
EŠects of Iso‰avones on Osteoblastic Cells
Osteoblasts play a role in the stimulation of bone formation and calciˆcation. The action of iso‰avones on osteoblastic cells in vitro is shown. [16] [17] [18] Osteoblastic MC3T3-E1 cells were cultured for 48 h in a serumfree a-MEM containing genistein or daidzein. The presence of genistein (10 -6 or 10 -5 M) or daidzein (10 -6 or 10 -5 M) caused a signiˆcant increase in protein content, alkaline phosphatase activity, and DNA content in the cells. The ability of genistein or daidzein to increase biochemical components in the cells is not seen in the presence of cycloheximide, suggesting that the eŠects of iso‰avone result from newly synthesized protein components. The anabolic eŠects of genistein in osteoblastic cells are not distinguishable from those of daidzein.
The eŠects of 17b-estradiol in increasing protein content and alkaline phosphatase activity in osteoblastic cells is not enhanced in the presence of genistein. 16 ) Cellular protein content was additively increased with 17b-estradiol and daidzein, but their eŠects on alkaline phosphatase activity were not additive. The receptors of estrogen are found in osteoblastic cells. 11, 12) Genistein has been shown to bind to estrogen receptor b in osteoblastic cells. 19) It is speculated that genistein or daidzein may bind to estrogen receptor b in osteoblastic cells, although the nuclear localization of genistein or daidzein in these cells has not been fully clariˆed.
DNA content in osteoblastic cells was signiˆcantly increased in the presence of genistein or daizein, suggesting that iso‰avones stimulate cell proliferation. 16, 17) Iso‰avones increase alkaline phosphatase activity, which is a marker enzyme in the diŠerentia-tion of osteoblastic cells. Genistein and daidzein may have stimulatory eŠects on the proliferation and diŠerentiation of osteoblastic MC3T3-E1 cells.
The cellular mechanism by which iso‰avones stimulate osteoblastic bone formation has been studied in relation to protein synthesis. The presence of genistein or daidzein stimulates protein synthesis in osteoblastic MC3T3-E1 cells in vitro. 18) The addition of genistein (10 -7 -10 -5 M) or daidzein (10 -7 -10 -5 M) to the reaction mixture of protein synthesis using the cell homogenate from osteoblastic cells cultured without iso‰avone caused a signiˆcant increase in protein synthesis in vitro. This increase is clearly suppressed in the presence of cycloheximide, indicating that genistein or daidzein can directly stimulate protein synthesis in vitro. Moreover, either of these iso‰avones was shown to increase [ 3 H]leucyl-tRNA synthetase activity in the cytosol fraction of osteoblastic cell homogenate. 18) Genistein had a greater eŠect than daidzein. Iso‰avone can directly activate leucyl-tRNA synthetase, a rate-limiting enzyme in the translational process of protein synthesis. 20) The possibility cannot be excluded that genistein or daidzein acts on the translational process in osteoblastic MC3T3-E1 cells, since the stimulatory eŠects of the iso‰avones on protein synthesis in osteoblastic cells are suppressed by actinomycin D. Genistein has been shown to bind to estrogen receptors in osteoblastic cells, 21) although daidzein cannot bind to estrogen receptors. 22) Moreover, it is possible that genistein or daidzein can bind to transcriptional proteins, which diŠer from estrogen receptors, in osteoblastic MC3T3-E1 cells. Whether iso‰avones have eŠects on various protein kinases and protein phosphatases that are related to osteoblastic cell proliferation and nuclear transcription activity must be determined.
As mentioned above, genistein and daidzein have anabolic eŠects in osteoblastic MC3T3-E1 cells. Iso‰avones may stimulate osteoblastic bone formation, supporting the observation that they have an overall stimulatory eŠect on bone formation and mineralization in bone tissue culture systems.
EŠects of Iso‰avones on Bone Resorption in Tissue Culture
Parathyroid hormone (PTH), prostaglandin E 2 , (PGE 2 ), and lipopolysaccharide (LPS) have stimulatory eŠects on bone resorption in in vitro culture system. [23] [24] [25] [26] Culture with PTH, PGE 2 , or LPS clearly stimulated bone resorption in the femoral-metaphyseal tissues cultured for 48 h, when bone resorption was estimated with a decrease in bone calcium content. 27) The eŠects of bone-resorbing factors were completely inhibited in the presence of genistein, indicating inhibition of bone resorption. 27) PTH and PGE 2 cause a remarkable increase in glucose consumption and lactic acid production by bone tissues. 27) The production of lactic acid by bone tissues may be related to the augmentation of glucose consumption. Presumably, PTH-and PGE 2 -stimulated lactic acid production by bone tissues can hasten a decrease in bone calcium content. Genistein completely inhibited the PTH-or PGE 2 -induced increase in both glucose consumption and lactic acid production by bone tissues. 27) The inhibitory eŠects of genistein on bone resorption are partly related to the prevention of lactic acid production by bone tissues.
Genistein has stimulatory eŠects on bone formation and mineralization in tissue culture in vitro. 32) the action of iso‰a-vones on osteoclastic cell formation may be related in part to inhibitory eŠects on the kinase. The cellular mechanism by which genistein inhibits osteoclast-like cell formation from marrow cells may be involved in cyclic AMP signaling. Genistein was found to induce cell death (apoptosis) of osteoclasts isolated from rat femoral tissues. 33) Calcitonin is known to inhibit osteoclast activity. 34) The hormonal eŠect may be mediated through the two pathways of cyclic AMP and Ca 2＋ signalings. 35) The addition of calcitonin, DcAMP, or calcium chloride to culture medium suppressed the number of osteoclasts isolated from rat femoral tissues. 33) The addition of dibucaine, an antagonist of calmodulin, or staurosporine, an inhibitor of protein kinase C, completely prevented the decrease in osteoclasts induced by calcitonin, DcAMP, or calcium chloride. 33) The eŠect of genistein in decreasing osteoclasts was clearly suppressed by these inhibitors, suggesting that the eŠects of iso‰avones on mature osteoclasts is partly mediated through the pathway of Ca 2＋ signaling.
A Ca 2＋ ionophore (A2387) caused a remarkable decrease in the number of osteoclasts, indicating that the entry of Ca 2＋ in the cells induces osteoclast death. 33) The number of osteoclasts was decreased when cultured with genistein or calcium chloride. Ca 2＋ can activate endonuclease and the metal induces apoptosis in cells. 36) The eŠect of A23187 in decreasing osteoclasts may be based on Ca 2＋ -activated DNA fragmentation, which induces apoptosis. Genistein has been reported to induce apoptosis in immature human thymocytes by inhibiting torosiomerase II. 37) Presumably, the iso‰avone stimulates apoptosis of osteoclasts, and its mechanism is partly related to the pathway of Ca 2＋ signaling. It may be possible that genistein stimulates Ca 2＋ entry into osteoclasts, since it has been reported that the iso‰avone can directly open a chloride channel in human cysticˆbrosis transmembranes. In addition, daidzein has also been shown to suppress the number of mature osteoclasts, 33) although daidzein does not have a greater suppressive eŠect than genistein. The eŠect of daidzein is completely abolished in the presence of dicucaine or staurosporine, supporting that the partial involvement of the Ca 2＋ -signaling mechanism. 33) Culture with genistein is found to induce a signiˆcant inhibition of protein kinase activity and an appreciable elevation of protein tyrosine phosphatase activity in osteoclasts. 38) Genistein has a strong inhibitory eŠect on protein tyrosine kinases. 32) The inhibition of these kinases may induce apoptosis in a human ovarian tumor cell line 32) and in Jurket T-leukemia cells. 39) Genistein may partly induce apoptosis of osteoclasts through a mechanism that inhibits protein tyrosine kinases in the cells. It has been shown that tyrosine kinase Src is implicated in the process of osteoclast-induced bone resorption in vitro and in vivo. 40) Culture with genistein is found to cause a signiˆcant increase in protein tyrosine phosphatase activity in osteoclasts. Such an eŠect is also seen with the addition of genistein to the enzyme reaction mixture in vitro. Genistein can directly activate protein tyrosine phosphatase in osteoclasts. Vanadate is an inhibitor of protein tyrosine phosphatase. The culture of osteoclasts with vanadate does not cause a decrease in the number of osteoclasts. The suppressive eŠect of genistein on osteoclasts is also seen in the presence of vanadate. 38) It has been reported that protein tyrosine phosphatase (Src homology 2 domain-containing tyrosine phosphatase) is a negative regulator of osteoclastogenesis and osteoclast-resorbing activity in mutant mice. 40) Presumably, the suppressive eŠect of genistein on mature osteoclasts is partly mediated through the activation of protein tyrosine phosphatase in the cells.
b-Glucuronidase is a lysosomal enzyme involved in stimulation of bone resorption by PTH. Genistein does not have an eŠect on b-glucuronidase activity in osteoclasts. 38) The eŠects of genistein on inhibition of osteoclastic bone resorption may not be implicated in the activity of lysosomal enzymes in the cells.
In conclusion, the suppressive eŠects of genistein on rat bone osteoclasts may be involved in the induction of apoptosis mediated through the Ca 2＋ signaling mechanism, inhibition of protein kinase, and activation of protein tyrosine phosphatase in the cells.
Preventive EŠects of Iso‰avones against Bone Loss Bone mass decreases with age. This decrease may be due to increased bone resorption and to decreased bone formation. Osteoporosis with a decrease in bone mass is widely recognized as a major public health problem. Genistein and daidzein have been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption, so that bone mass is increased, as shown in Fig. 2 . Iso‰avones may have the potential to prevent bone loss with increasing age.
Nijiru, which is a by-product in the fermentation process of soybeans to make natto, contains large quantities of natural iso‰avone. Nijiru is a functional food factor as a dietary iso‰avones. The oral administration of the iso‰avone-containing soybean extract (nijiru) to rats caused a signiˆcant increase in bone components (calcium, alkaline phosphatase, and DNA) in the femoral-diaphyseal and -metaphyseal tissues in vivo, 41, 42) indicating its anabolic eŠects on bone metabolism.
Ovarian hormone deˆciency at menopause stimulates bone loss. 43, 44) Ovariectomy (OVX) causes a lack of estrogen, and the hormone deˆciency induces osteoporosis in humans. Bone weight, bone mineral density, and bone mineral content are reduced in OVX rats. 45) These reductions were signiˆcantly prevented by feeding with fermented soybeans with nijiru supplementation containing iso‰avones for 3 months, 45) indicating that OVX-induced bone loss can be prevented by the prolonged intake of dietary iso‰avone supplementation.
A supplement made from Nijiru powder was shown to enhance bone healthy in individuals. Twelve volun-teers (six men and six women) received nijiru twice a day for 60 days at a dose of 1500 mg (6 tablets) per day. Serum g-carboxylated osteocalcin concentration was signiˆcantly increased with the intake of nijiru in both sexes to about 2-fold that in the control group. 46) The intake of iso‰avone-containing nijiru as a supplement may thus have a role in the prevention of age-related bone loss.
Whether the combination of nutritional factors has an additive or synergistic eŠect on bone components has not been determined, and this knowledge may be important in the prevention of bone loss with age. The combination of genistein and zinc was found to have a synergistic eŠect on bone components in femoral tissue from elderly female rats in vitro and in vivo. [47] [48] [49] Zinc, an essential trace element, has been demonstrated to have a potent stimulatory eŠect on bone formation and an inhibitory eŠect on bone resorption, supporting its preventive eŠect on bone loss with aging. [50] [51] [52] The eŠects of experimental diets with fermented soybeans containing genistein and zinc on OVX-induced bone loss has been demonstrated. 53) Experimental diets containing 2.1 to 9.7 mg of zinc per 100 g of diet and 44.6 to 92.4 mg of iso‰avones (including genistein, genistin, daidzin, and daidzein) per 100 g of diet was fed to OVX rats for 3 months. OVX caused a signiˆcant reduction in the dry weight, mineral density, calcium content, zinc content, and alkaline phosphatase activity in femoral tissues. 53) The reductions were largely prevented by feeding a natto diet. This prevention was signiˆcantly enhanced in OVX rats fed a natto diet supplemented with iso‰a-vone and zinc. The prolonged intake of dietary natto supplemented with iso‰avone and zinc has a preventive eŠect on OVX-induced bone loss, suggesting that it may have a role in the prevention of osteoporosis.
It has also been shown that the intake of zinc-supplemented natto has a potent stimulatory eŠect on bone formation and an inhibitory eŠect on bone resorption in aged individuals. 54) The prolonged intake of dietary iso‰avone-rich natto supplemented with zinc may be useful for bone health and the prevention of bone loss.
Casein phosphopeptides (CPP), a product of tryptic casein digestion, have been shown to enhance paracellular transport of calcium in the distal small intestine. 55, 56) Genistein or CPP was orally administered to young (5 weeks old) or elderly (50 weeks old) female rats for 14 days. 57, 58) The genisteininduced increase in femoral dry weight and bone components was signiˆcantly enhanced by the simultaneous administration of CPP. 58) The combination of genistein and CPP administration has an synergistic anabolic eŠect on bone components in rats with increasing age. The combination of genistein and CPP in dietary supplementation may be a good tool for the prevention of bone loss with aging.
MENAQUINONE-7 AND BONE METABOLISM
Vitamin K 2 is essential for the g-carboxylation of osteocalcin, a bone matrix protein containing g-carboxyglutamic acid, which is synthesized only in osteoblasts. 59, 60) Noncarboxylated osteocalcin cannot bind to hydroxyapatite in bone tissues. 60, 61) Much attention has been paid to the role of vitamin K in bone metabolism. The chemical structure of vitamin K is shown in Fig. 3 . There are three types of vitamin K: vitamin K 1 (phylloquinone), vitamin K 2 (menaquinone), and vitamin K 3 (menadione). Vitamin K 1 is a sole compound, but vitamin K 2 is a series of vitamers with multiisoprene units (1 to 4) at the 3-position of the naphthoquinone. Several reports have indicated the eŠects of vitamin K 1 on bone metabolism. 62, 63) In contrast, the eŠects of vitamin K 2 on bone metabolism have not attracted notice. Like vitamin K 1 , vitamin K 2 (menatetrenone), with four isoprene units, not only enhances mineralization but also increases the amount of osteocalcin in cultured human osteoblasts. 64) It has also been reported that menatetrenone inhibits bone resorption, which may be related to its side chain 65) and that the compound inhibits bone loss induced by ovariectomy in rats. 66) Natural vitamin K 2 (menaquinone-7; MK-7) with seven isoprene units is abundant in fermented soybeans (natto). The eŠects of MK-7 on bone metabolism have not been clariˆed. We found that MK-7 has an anabolic eŠect on bone calciˆcation in rat femoral tissues. 67) MK-7 may play a role in the prevention of bone loss with increasing age.
EŠects of MK-7 on Osteoblastic Bone Formation MK-7 has been found to have a stimulatory eŠect on calciˆcation in the femoral tissues obtained from normal young rats in vitro. 67) Culture with MK-7 (10 -6 or 10 -5 M) caused a signiˆcant increase in biochemical components (calcium content, alkaline phosphatase activity, and DNA content) in the femoral-diaphyseal (cortical bone) and -metaphyseal (trabecular bone) tissues obtained from aged rats in vitro. 68) This eŠect was signiˆcantly enhanced in the presence of genistein (10 -6 or 10 -5 M), suggesting that the mode of action of MK-7 diŠers from that of genistein. The eŠect of MK-7 in increasing bone components in the femoral tissues was completely abolished in the presence of cycloheximide, an inhibitor of protein synthesis in vitro. MK-7 has a stimulatory eŠect on bone formation in the femoral tissues of elderly female rats in vitro.
Osteoblastic MC3T3-E1 cells at subcon‰uency were cultured for 24 hr in a serum-free medium containing MK-7 (10 -7 -10 -5 M). Culture with MK-7 (10 -6 or 10 -5 M) caused a signiˆcant increase in protein content, alkaline phosphatase activity, and DNA content in osteoblastic cells. 69) The eŠect of MK-7 on cellular alkaline phosphatase activity and osteocalcin content was completely prevented with cycloheximide. MK-7 has a stimulatory eŠect on osteoblastic bone formation due to increasing protein synthesis.
EŠects of MK-7 on Osteoclastic Bone Resorption Culture with bone-resorbing factors (PTH or PGE 2 ) caused a signiˆcant decrease in calcium content in the femoral-metaphyseal tissues obtained from young and aged rats in vitro. 70, 71) The bone-resorbing factorinduced decrease in metaphyseal calcium content was completely prevented with MK-7 (10 -7 -10 -5 M) culture, indicating that MK-7 has an inhibitory eŠect on bone resorption in bone tissue culture. In addition, MK-7 (10 -7 -10 -5 M) completely prevented the PTH-or PGE 2 -induced increase in medium glucose consumption and lactic acid production by bone tissues in vitro. 71) The preventive eŠect of MK-7 on bone resorption may partly result from the inhibition of the PTH-or PGE 2 -stimulated medium glucose consumption and lactic acid production by bone tissues. PTH can stimulate extracellular release of lactic acid from osteoclastic cells. The PTH-induced increase in lactic acid production may result from the consumption of glucose by osteoclastic cells. This acid production is important as a cellular mechanism of bone resorption.
Osteoclast-like cells are formed from bone marrow cells in the presence of bone-resorbing factors (PTH or PGE 2 ). The PTH-or PGE 2 -induced increase in osteoclast-like cell formation is signiˆcantly inhibited by MK-7 (10 -8 -10 -5 M). 70) MK-7 has a more potent inhibitory eŠect at the later stage of diŠerentiation of marrow cells. Osteoclast-like cell formation was stimulated when dibutyryl cyclic AMP (DcAMP) or phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, was added to the culture. MK-7 signiˆcantly inhibited the eŠect of PMA on osteoclast-like cell formation, although it did not have an inhibitory eŠect on the DcAMP-induced increase in osteoclast-like cell formation. These observations suggest that the inhibitory action of MK-7 is partly involved in protein kinase C signaling. 70) The eŠect of MK-7 on mature osteoclasts isolated from rat femoral tissues was examined. 70) Culture with MK-7 (10 -6 or 10 -5 M) caused a signiˆcant decrease in the number of mature osteoclasts. Such a decrease was also seen in the presence of calcitonin, DcAMP, or calcium chloride. The eŠect of MK-7 in decreasing the number of osteoclasts was not further enhanced in the presence of calcitonin, DcAMP, or calcium chloride, and it was completely abolished in the presence of dibucaine or staurosporine, which are inhibitors of Ca 2＋ -dependent protein kinases. The suppressive eŠect of MK-7 on osteoclasts may be partly mediated through the pathway of Ca 2＋ -and cyclic AMP-dependent signaling.
Preventive EŠects of MK-7 on Bone Loss MK-7 has been demonstrated to have a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on bone resorption, thereby increasing bone mass, as shown in Fig. 4 . The preventive eŠect of dietary MK-7 on bone loss was investigated using OVX rats. 72, 73) OVX rats were given experimental diets containing menaquinone-4 (MK-4; 12 mg/100 g diet) or menaquinone-7 (MK-7; 18.1 mg/100 g diet) for 24 days: MK-4 and MK-7 were equal in molar concentrations. This feeding caused a remarkable increase in MK-4 and MK-7 concentrations in the serum and femur of OVX rats. OVX-induced decreases in the femoral dry weight and femoral calcium content were prevented by feeding with dietary MK-4 or MK-7. In separate experiments, OVX rats were given experimental diets containing fermented soybeans (natto; including MK-7 9.4 mg/100 g diet) with or without added MK-7 (37.6 mg/100 g diet) for 77 days. Feeding produced a signiˆcant elevation of MK-4 and MK-7 concentrations in the serum of OVX rats. The decreases in the femoral dry weight and femoral calcium content induced by OVX were signiˆcantly prevented by feeding with diets containing natto with MK-7 added (37.6 mg/100 g diet). Such an eŠect is not seen with diets containing natto without MK-7 or both MK-7 and iso‰avone. The intake of dietary MK-7 had a preventive eŠect on bone loss caused by OVX. This eŠect may be partly caused by MK-4, which is formed by degradation of MK-7.
The eŠect of the prolonged intake of dietary MK-7 on bone loss in OVX rats was also investigated. OVX rats were given experimental diets containing fermented soybeans (including MK-7 9.4 mg/100 g diet) with or without supplemental MK-7 (containing 14.1 or 18.8 mg of MK-7/100 g diet) for 150 days. Feeding produced a signiˆcant elevation of the MK-7 serum concentration of OVX rats. The serum g-carboxylated osteocalcin concentration was signiˆcantly decreased by OVX. This decrease was signiˆcantly prevented by the feeding of natto diets with supplemental MK-7 (18.8 mg/100 g diets). OVX caused a signiˆcant decrease in femoral dry weight, femoral calcium content, and mineral density. These decreases were signiˆcantly prevented by feeding with diets containing natto with MK-7 (total, 18.8 mg/100 g diet).
The prolonged intake of natto with MK-7 has a preventive eŠect on bone loss induced by OVX. Dietary MK-7 may be useful in the prevention of osteoporosis.
EŠects of MK-7 in Normal Individuals
The change in circulating MK-7 and g-carboxylated osteocalcin (Gla osteocalcin) concentrations in normal individuals with the intake of fermented soybean (natto) was examined. 74, 75) Forty-eight volunteers (45 men and 3 women) were divided into three groups of 16 volunteers each (15 men and 1 women), and each group was given sequentially fermented soybeans (50 g) containing three diŠerent amounts of MK-7 once a day for 14 days as follows: either regular natto with MK-7 865 mg/100 g of natto, reinforced natto containing MK-7 1295 mg/100 g, or MK-7 1730 mg/100 g. Serum MK-7 was not found in normal individuals who had not eaten natto. Serum MK-7 and g-carboxylated osteocalcin concentrations were signiˆcantly raised 7, 10, and 14 days after the start of the intake of reinforced natto containing MK-7 1295 or 1730 mg/100 g. Serum g-carboxylated osteocalcin levels were not signiˆcantly elevated with the intake of regular natto, although serum MK-7 levels were signiˆcantly raised. Moreover, serum g-carboxylated osteocalcin concentration was signiˆcantly elevated 14 days after the intake of natto containing either 1295 or 1730 mg of MK-7/100 g diet, as compared with that after regular natto intake. The intake of dietary MK-7 in reinforced natto can stimulate g-carboxylation of osteocalcin, which plays an important role in bone formation in normal individuals.
Epidemiologic data indicate that the intake of natto may play a role in the prevention of osteoporosis. 76) However, it has not been determined whether the prolonged intake of dietary natto causes an increase in MK-7 and a corresponding increase in g-carboxylated osteocalcin in the serum of normal individuals. The appropriate amount of dietary MK-7 may have a stimulatory eŠect on bone mineralization in those individuals. The intake of reinforced natto that contains more MK-7 than regular natto may participate in the prevention of age-related bone loss.
A combination of nutritional factors may have an additive or synergistic eŠect on bone loss with increasing age. Zinc has been shown to enhance the eŠect of MK-7 in increasing bone calcium-content in vitro. 67) The combined administration of zinc and MK-7 was found to have a synergistic or additive enhancing eŠect on bone components in the femoral tissues of female elderly rats. 77) Supplemental intake of zinc and MK-7 may be useful in preventing osteoporosis with increasing age.
b-CRYPTOXANTHIN AND BONE METABOLISM
Retinol (vitamin A) is known to have a detrimental eŠect on bone at high doses. In laboratory animals, high levels of vitamin A lead to accelerated bone resorption, bone fractures, and osteoporotic bone lesions. [78] [79] [80] The eŠect of carotenoids on bone metabolism, however, have not been fully clariˆed. Carotenoids are present in fruit and vegetables.
Of the various carotinoids and rutin examined, bcryptoxanthin was found to have a unique anabolic eŠect on bone calciˆcation in vitro. 81) b-Cryptoxanthin is carotenoid abundant in Satsuma mandarin (Citrus unshiu MARC), and it is enzymatically converted from b-caroteine (provitamin A) in plants. The biological eŠect of b-cryptoxanthin has not been fully clariˆed. The chemical structure of b-cryptoxanthin is shown in Fig. 5 .
EŠects of b-Cryptoxanthin on Osteoblastic Bone Formation
The eŠects of various carotenoids and rutin on calcium content and alkaline phosphatase activity in the femoral-diaphyseal (cortical bone) and metaphyseal (trabecular bone) tissues of young rats in vitro were investigated. Culture with b-cryptoxanthin (10 -7 or 10 -6 M) caused a signiˆcant increase in calcium content and alkaline phosphatase activity in the femoral-diaphyseal and -metaphyseal tissues. Lutein, lycopene, and rutin 10 -8 to 10
-6 M did not have anabolic eŠects on calcium contents and alkaline phosphatase activity in rat femoral-diaphyseal and -metaphyseal tissues. b-Carotene (10 -6 or 10
had no eŠect on the diaphyseal and metaphyseal calcium contents. b-Cryptoxanthin had a unique anabolic eŠect on bone calciˆcation in vitro. 81) Moreover, culture with b-cryptoxanthin (10 -6 or 10 -5 M) caused a signiˆcant increase in DNA content in the femoral tissues. 82) It has been reported that the serum concentration of b-cryptoxanthin due to consumption of vegetable juice in women is in the range of 1.3×10 
10
-6 M caused a signiˆcant anabolic eŠect on biochemical components in rat femoral tissues in vitro, suggesting a physiologic role in the regulation of bone metabolism.
b-Cryptoxanthin was found to stimulate the proliferation of osteoblastic cells in subcon‰uent monolayers in a medium containing 10％ FBS. 84) Culture with b-cryptoxanthin also caused a signiˆcant increase in biochemical components of osteoblastic cells. 84) The eŠect of b-cryptoxanthin on osteoblastic cell components seems to be partly mediated through protein kinase C or MAP kinase in the cells, since the carotenoid eŠects are inhibited by various inhibitors of intracellular signaling factors.
The eŠects of b-cryptoxanthin in increasing protein content, alkaline phosphatase activity, and DNA content in osteoblastic cells are completely inhibited in the presence of DRB, an inhibitor of RNA polymerase II. This suggests that b-cryptoxanthin has a stimulatory eŠect on transcriptional activity in osteoblastic cells. b-Cryptoxanthin is enzymatically converted from b-caroteine (provitamin A) in plants. Vitamin A (retinol) may be able to bind to nuclear receptors. It is speculated that b-cryptoxanthin binds to nuclear receptors in osteoblastic cells, and that the carotenoid transcriptional activity occurs in the cells.
Culture with b-cryptoxanthin stimulates the expression of insulin-like growth factor (IGF-I) or transforming growth factor (TGF)-b1 mRNA in osteoblastic cells using RT-PCR analysis. 84) Thisˆnding may support the view that b-cryptoxanthin has a stimulatory eŠect on transcriptional activity in osteoblastic cells. IGF-I or TGF-b1, which is a bone growth factor, is produced from osteoblasts. 85, 86) The anabolic eŠect of b-cryptoxanthin in osteoblastic cells may be partly mediated through the action of IGF-I or TGF-b1 produced from the cells.
b-Cryptoxanthin (10 -7 or 10 -6 M) has also been found to increase the expression of Runx2, a1(I) collagen, and alkaline phosphatase mRNAs in osteoblastic MC3T3-E1 cells. 87) Runx2 (Cbfa 1) is a member of the runt domain family of transcription factors, and it is involved in bone development. 88) a1(I) collagen is a matrix protein that is related to bone formation and mineralization in osteoblast lineage cells. 89) Alkaline phosphatase participates in the mineralization process in osteoblastic cells. 90) b-Cryptoxanthin has a stimulatory eŠect on the expression of genes for proteins involved in osteoblasic bone formation.
The eŠects of b-cryptoxanthin in stimulating Runx2, a1(I) collagen, and alkaline phosphatase mRNA expression in osteoblastic MC3T3-E1 cells was found to be prevented completely in the presence of DRB. 87) This result may support the view that bcryptoxanthin stimulates transcriptional activity in osteoblastic MC3T3-E1 cells.
Vitamin A has been shown to stimulate the function of mouse osteoblastic cells. 91) Retinol and bcarotene inhibit the proliferation of osteoblastic MC3T3-E1 cells as well as DNA synthesis of the cells. Retinol induces diŠerentiation of MC3T3-E1 cells by increasing alkaline phosphatase activity dose dependently (10 -9 -10 -7 M). 91) We conˆrmed that vitamin A (10 -7 or 10 -6 M) increases alkaline phosphatase activity in osteoblastic cells. b-Cryptoxanthin (10 -7 or 10 -6 M) caused a signiˆcant increase in alkaline phosphatase activity and protein content in osteoblastic cells. This eŠect of b-cryptoxanthin was also seen in the presence of vitamin A (10 -6 M). Moreover, the stimulatory eŠect of b-cryptoxanthin on the expression of Runx2 type 1 and a1(I) collagen mRNA was also observed in the presence of vitamin A. Vitamin A did not have a signiˆcant eŠect on Runx2 type 1 mRNA expression in osteoblastic MC3T3-E1 cells. Thus the mode of action of b-cryptoxanthin on gene expression in osteoblastic cells may diŠer from that of vitamin A, which is mediated through the RXR receptor in the nucleus of the cells. 92) It is speculated that b-cryptoxanthin may be able to bind other receptors (including orphan receptors), and that the carotenoid may stimulate transcriptional activity in osteoblastic cells.
Prolonged culture with b-cryptoxanthin is found to stimulate mineralization. b-Cryptoxanthin signiˆ-cantly stimulated cell number, DNA content, protein content, and alkaline phosphatase activity in osteoblastic MC3T3-E1 cells when the cells were cultured for 3 to 21 days. 84) b-Cryptoxanthin has a stimulatory eŠect on cell diŠerentiation and mineralization in osteoblastic cells. The process of the action of b-cryptoxanthin in stimulating mineralization in osteoblastic cells is summarized in Fig. 6 .
EŠects of b-Cryptoxanthin on Osteoclastic Bone Resorption
Culture with the bone-resorbing factor PTH or PGE 2 caused a signiˆcant decrease in calcium content in the diaphyseal and metaphyseal tissues. This decrease was completely inhibited by bcryptoxanthin (10 -8 -10 -6 M). In addition, b-cryptoxanthin completely inhibited the PTH-or PGE 2 -induced increase in medium glucose consumption and lactic acid production by bone tissues. 82) b-Cryptoxanthin has an inhibitory eŠect on bone resorption in tissue culture in vitro.
b-Cryptoxanthin (10 -8 -10 -6 M) has been shown to have a potent inhibitory eŠect on osteoclast-like cell formation in mouse marrow culture in vitro. 93) Culture with b-cryptoxanthin caused a marked inhibition of osteoblast-like cell formation induced in the presence of PTH, PGE 2 , VD 3 , LPS, or tumor necrosis factor-a (TNF-a). The inhibitory eŠect of b-cryptoxanthin was equal to that of 17b-estradiol, calcitonin, genistein, and zinc sulfate, which can inhibit osteoclast-like cell formation induced by bone-resorbing factors.
The inhibitory eŠect of b-cryptoxanthin on osteoclast-like cell formation was seen at the later stage of osteoclast diŠerentiation in bone marrow cultures. This suggests that the carotenoid has a potent eŠect on the process of diŠerentiation from mononuclear osteoclast to osteoclast. The receptor activator of NFkB ligand (RANKL) acts on osteoclast progenitors, and the cytokine stimulates osteoclast diŠerentia-tion. 94, 95) RANKL plays a pivotal role in osteoclast diŠerentiation. b-Cryptoxanthin had a signiˆcant inhibitory eŠect on osteoclast-like cell formation induced by RANKL.
RANKL expression is induced in osteoblastic cells and bone marrow stromal cells in response to osteoporotic factors, such as PTH, PGE 2 , and VD 3 , and combined treatment of hematopoietic cells with macrophage colony-stimulating factor (M-CSF) and the soluble form of RANKL (sRANKL) induces osteoclast diŠerentiation in vitro. The receptor protein RANK is expressed on the surface of osteoclast progenitors. The supporting cells (osteoblasts or stromal cells) are not required for this activity. b-Cryptoxanthin signiˆcantly inhibited osteoclast-like cell formation induced by PTH, PGE 2 , and VD 3 in mouse marrow cultures. Presumably, the inhibitory eŠect of the carotenoid is partly involved in RANKL expression, which is related to the eŠects of PTH, PGE 2 , or VD 3 .
LPS-or TNFa-induced osteoclast-like cell formation in mouse marrow cultures was signiˆcantly prevented by b-cryptoxanthin. 93) TNF-a is an autocrine factor in osteoclasts, promoting their diŠerenti-ation and mediates RANKL induction of osteoclastogenesis. 96) TNF-a has also been shown to mediate via its p55 receptor in LPS-stimulated osteoclastogenesis. The inhibitory eŠect of b-cryptoxanthin on TNFa-or LPS-stimulated osteoclastogenesis may be a combination of eŠects by locally produced RANKL and LPS or TNF-a.
The interaction of RANKL with its receptor RANK leads to the recruitment of the signaling adaptor molecules TNF receptor-associated factors (TRAFs) to the receptor complex and the activation of NF-kB or c-Jun N-terminal kinase (JNK). 97) A protein kinase C family enzyme has a role in the regulation of osteoclast formation and function, potentially by participating in the extracellular signal-regulated kinase (ERK) signaling pathway of M-CSF and RANKL.
Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C. PMA signiˆcantly stimulated osteoclast-like cell formation in mouse marrow cultures, and the PMA-induced osteoclastogenesis was signiˆcantly inhibited by b-cryptoxanthin. 93) bCryptoxanthin may have a suppressive eŠect on the cellular response that is mediated through the binding of RANKL to RANK receptors in osteoclastogenesis.
In addition, b-cryptoxanthin did not have an inhibitory eŠect on RANKL expression in osteoblastic cells. 93) It is possible that b-cryptoxanthin has an eŠect on the expression of osteoprotegerin (ORG), a regulated suppressor of osteoclast diŠerentiation, in osteoblasts. The action of b-cryptoxanthin in inhibiting osteoclastogenesis is summarized in Fig. 7 .
EŠects of b-Cryptoxanthin on Mature Osteoclasts The eŠects of b-cryptoxanthin on mature osteoclasts were investigated. M-CSF-dependent bone marrow macrophages were cultured in the presence of M-CSF Apoptosis-related gene expression was determined using RT-PCR. 98) Culture with b-cryptoxanthin caused a signiˆcant increase in caspase-3 mRNA expression in the presence or absence of M-CSF and RANKL, while Bcl-2 and Apaf-2 mRNA expressions were signiˆcantly increased in culture with b-cryptoxanthin without M-CSF and RANKL. Akt-1 mRNA expression was not signiˆcantly changed with culture when the carotenoid.
The expression of caspase-3 mRNA or Apaf-2, which involves apoptosis, in osteoclastic cells was found to be stimulated when cultured with b-cryptoxanthin in the absence of M-CSF and RANKL. 98) bCryptoxanthin stimulated caspase-3 mRNA expression in the presence of M-CSF and RANKL expression in the presence of M-CSF and RANKL. 98) bCryptoxanthin-induced apoptotic cell death is partly mediated through caspase-3 expression in osteoclastic cells. In addition, the expression of Bcl-2 mRNA, which is involved in rescue of apoptosis, is signiˆcant-ly decreased in b-cryptoxanthin culture in the presence or absence of M-CSF and RANKL. 98) However, Akt-1 mRNA expression is not signiˆcantly changed in culture with b-cryptoxanthin. The decrease in Bcl-2 mRNA expression may partly contribute to the eŠect of b-cryptoxanthin in stimulating the apoptotic cell death of osteoclastic cells.
Culture with b-cryptoxanthin was found to have suppressive eŠects on tartrate-resistant acid phosphatase (TRACP) activity, TRACP, and cathepsin K mRNA expression in osteoclastic cells in the presence or absence of M-CSF and RANKL. Presumably, bcryptoxanthin has inhibitory eŠects on the activation of mature osteoclasts. b-Cryptoxanthin has stimulatory eŠects on apoptotic cell death and suppressive eŠects on osteoclastic cell function.
Preventive EŠects of b-Cryptoxanthin against Bone Loss b-Cryptoxanthin has been shown to have a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on osteoclastic bone resorption in vitro. 82) The anabolic eŠect of b-cryptoxanthin on bone components in vivo was investigated. b-Cryptoxanthin (10, 25, or 50 mg/100 g body weight) was orally administered once daily for 7 days to young male rats. 99) The administration of b-cryptoxanthin (10, 25, or 50 mg/100 g body weight) caused a signiˆcant increase in calcium content and alkaline phosphatase activity in the femoral-diaphyseal and -metaphyseal tissues. Femoral-diaphyseal and -metaphyseal DNA contents were signiˆcantly increased by the dose of 25 or 50 mg/100 g body weight. b-Cryptoxanthin has an anabolic eŠect on bone components in rats in vivo. Such an eŠect is also observed in the femoral tissues of aged (50-week-old) female rats. 100) To determine whether b-cryptoxanthin has a preventive eŠect on bone loss in the pathophysiologic state, the eŠects of b-cryptoxanthin on bone components of streoptozotocin (STZ)-diabetic rats were determined. 101) Young rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and then the animals were orally administered b-cryptoxanthin (5 or 10 mg/100 g body weight) once daily for 7 or 14 days. The administration of STZ caused a signiˆcant decrease in body weight and a signiˆcant increase in serum glucose, triglyceride, and calcium levels, indicating a diabetic state. These alterations were signiˆcantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/ 100 g) for 14 days. The administration of b-cryptoxanthin (5 or 10 mg/100 g) to normal rats for 14 days did not have a signiˆcant eŠect on body weight or on serum glucose, triglyceride, and calcium levels. Calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues were signiˆcantly decreased in STZ-diabetic rats. These decreases were signiˆcantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/ 100 g) for 14 days. Thus the intake of b-cryptoxanthin was found to have a preventive eŠect on bone loss in STZ-diabetic rats.
The eŠect of b-cryptoxanthin on OVX-induced bone loss was examined. 102) b-Cryptoxanthin (5 or 10 mg/100 g body weight) was orally administered once daily for 3 months to OVX rats. The analysis using peripheral quantitative computed tomography (pQCT) showed that OVX induced a signiˆcant decrease in mineral content and mineral density in the femoral-diaphyseal and -metaphyseal tissues. These decreases were signiˆcantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g). Moreover, OVX induced a signiˆcant decrease in calcium content and alkaline phosphase activity in the femoral-diaphyseal and -metaphyseal tissues and DNA content in the metaphyseal tissues. These decreases were signiˆcantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g). b-Cryptoxanthin has a preventive eŠect on OVX-induced bone loss in vivo.
EŠects of b-Cryptoxanthin in Normal Individuals Changes in circulating biochemical markers of bone metabolism in normal individuals with the intake of juice prepared from Satsuma mandarin containing bcryptoxanthin were investigated. Twenty-one volunteers (10 men and 11 women) were divided into two groups of 10 volunteers (5 men and 5 women) and 11 volunteers (5 men and 6 women), and each group was sequentially given juice (192 ml) containing two diŠerent amounts of b-cryptoxanthin once a day for 28 or 56 days: either regular juice with naturally occurring b-cryptoxanthin 802 mg/100 ml or a reinforced juice containing b-cryptoxanthin 1500 mg/100 ml. 103) As serum bone markers, bone-speciˆc alkaline phosphatase, g-carboxylated osteocalcin, bone TRACP, and N-telopeptide of type I collagen were determined. The intake of regular juice for 28 or 56 days caused a signiˆcant increase in g-carboxylated osteocalcin, a marker of bone formation. Intake for 56 days produced a signiˆcant decrease in serum bone TRACP activity. Moreover, the intake of the b-cryptoxanthin-reinforced juice for 28 or 56 days caused a signiˆcant increase in the serum g-carboxylated osteocalcin concentration and a corresponding decrease in serum bone TRACP activity and N-telopeptide of type I collagen, a marker of bone resorption. The intake of b-cryptoxanthin-reinforced juice thus has a stimulatory eŠect on bone formation and an inhibitory eŠect on bone resorption in normal individuals. 103) The serum b-cryptoxanthin concentration was signiˆcantly increased with the intake of regular juice for 56 days. This increase was signiˆcantly enhanced by the intake of b-cryptoxanthin-reinforced juice. 104) A positive relationship between serum b-cryptoxanthin and circulating g-carboxylated osteocalcin concentration was found using the value obtained from all groups for before intake and with the intake of regular juice and b-cryptoxanthin-reinforced juice. A negative relationship between serum b-cryptoxanthin concentration and circulating TRACP activity was observed. A relationship between serum b-cryptoxanthin and circulating bone metabolic markers was found in healthy individuals with the intake of juice containing b-cryptoxanthin. 104) Thus the intake of dietary b-cryptoxanthin may have a preventive eŠect on bone loss in humans with increasing age.
EFFECTS OF OTHER FOOD AND PLANT FACTORS ON BONE METABOLISM
As mentioned above, iso‰avones, menaquinone-7, and b-cryptoxanthin have been shown to have a stimulatory eŠect on bone formation and an inhibitory eŠect on bone resorption, thereby increasing bone mass. These food factors may have a preventive eŠect on bone loss with increasing age. Moreover, the identiˆcation of other food and plant factors may be important in the prevention of osteoporosis. Further study was undertaken to determine the eŠect of various food and plant extracts on bone metabolism.
EŠects of Wasabi Leafstalk Extract on Bone Metabolism
The eŠects of 20％ ethanol extracts obtained from various food and plants on bone calcium content were examined using bone tissues in vitro. Of various food and plants (including katsuo-bushi, loquat leaf, cherry leaf, dried shiitake, raw shiitake, gabaron tea, green tea, muskmelon, tomato, and blueberry) examined, wasabi leafstalk (Wasabi japonica MATSUM) extract was found to have an anabolic eŠect on bone calciˆcation in mouse calvaria tissue culture in vitro. 105) Wasabi leafstalk extract was obtained from a homogenate with 20％ ethanol. The presence of wasabi leafstalk extract (10 mg/ml) caused a signiˆcant increase in calcium content and alkaline phosphatase activity in bone tissues. With higher concentrations (50 and 250 mg/ml), however, the eŠect was weakened. The wasabi leafstalk extractinduced increase in bone calcium content was completely prevented by coculture with cycloheximide, an inhibitor of protein synthesis, suggesting that the eŠect of wasabi leafstalk extracts is based on newly synthesized protein components. In addition, wasabi leafstalk has an inhibitory eŠect on PTH-induced osteoclast-like cell formation in a mouse marrow culture system, suggesting that the component inhibits bone resorption (unpublished data).
The stimulatory eŠect of wasabi leafstalk extract on bone calciˆcation was compared with the anabolic eŠects of insulin, IGF-I, 17b-estradiol, and genistein. 106) The combination of 10 -10 M of 17b-estradiol and 15 mg/ml of wasabi leafstalk extract had an additive eŠect on bone calcium content. The combination of either insulin 10 -8 or 10 -7 M with wasabi leafstalk extract (15 mg/ml) had an additive eŠect. Such an eŠect was not seen in the case of IGF-I (10 -8 M). Wasabi leafstalk extract has an enhancing eŠect on the anabolic action of 17b-estradiol or insulin, which physiologically regulates bone formation and calciˆcation in vitro.
The components of the wasabi leafstalk extracts which increase bone calcium content were stable when treated with heating or with acidity or alkalinization. 107) The active component of wasabi leafstalk extract thus may not be a protein.
The active component in wasabi leafstalk was puriˆed. 108) Wasabi leafstalk extract was obtained from a homogenate with 20％ ethanol. The active component, which was found in the ethanol extract, was puriˆed upon gelˆltration chromatography with a HiLoad 26/80 Superdex 30-pg column and reversephase chromatography on a Resource 15 RPC 3-ml column. The result of ESI mass spectra of the puriˆed active component showed that its material had a molecular weight of 158. The material with a low molecular weight of 158 was the active component in wasabi leafstalk which stimulates bone calciˆcation. The identiˆcation of chemical structure is in progress.
To determine the anabolic eŠect of wasabi leafstalk extract on bone components in vivo, extracts (10-40 mg/100 g body weight) were orally administered once daily for 7 days in young and aged rats. 109, 110) The biochemical components in the femoral-diaphyseal and -metaphyseal tissues of young and aged rats was signiˆcantly increased by the administration of wasabi leafstalk extract for 7 days in vivo. Meanwhile, body weight, serum calcium, and inorganic phosphorus concentrations of the rats were not signiˆcantly altered by the administration of wasabi leafstalk extract for 7 days. Wasabi leafstalk extract therefore has an anabolic eŠect on bone components in vivo. The intake of wasabi leafstalk extract may have a preventive eŠect on bone loss.
EŠects of Marine Alga Extract on Bone Metabolism
The eŠect of marine algae on bone metabolism has not yet been clariˆed. We determined the eŠects of various marine algae on bone calciˆcation in the femoral tissues of rats in vitro. 111) Undaria pinnatiˆda, Sargassum horneri, Eisenia bicyclis, Cryptonemia scmitziana, Gelidium amansii, and Ulva pertusa Kjellman, which were gathered seasonally, were used. Water suspensions (5％) of marine alga powder were orally administered once daily for 7 days. Bone calcium content was signiˆcantly increased by the administration of U. pinnatiˆda, S. horneri, E. bicyclis, or C. scmitziana. Bone alkaline phosphatase activity, which is an enzyme for calciˆcation, was signiˆcantly enhanced with the administration of S. horneri or G. amansii. Femoral-metaphyseal tissues were cultured in medium containing water-solubilized extract (25 and 50 mg/ml) obtained from U. pinnatiˆda, S. horneri, E. bicyclis, and C. scmitziana. The bone calcium content was signiˆcantly elevated in the presence of S. horneri extract (25 and 50 mg/ml). No eŠect was seen with the other extracts. S. horneri extract has a unique anabolic eŠect on bone calciˆcation in vivo and in vitro. The eŠects of S. horneri extract in increasing calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues was completely abolished in the presence of cycloheximide, an inhibitor of protein sythesis. 112) The anabolic eŠect of S. horneri extract may be based on newly synthesized protein components. The eŠect of S. horneri extract on bone resorption in vitro was examined. 113) The PTH-and PGE 2 -induced decrease in bone calcium content was completely inhibited by water-solubilized extracts (10, 25, and 50 mg/ml) of S. horneri. In addition, these extracts (25 and 50 mg/ml) completely inhibited the PTH-or PGE 2 -induced increase in medium glucose consumption and lactic acid production by bone tissues. Moreover, S. horneri extracts (10-50 mg/ml) blocked the PTH-induced increase in acid phosphatase activity in the diaphyseal and metaphyseal tissues. Theseˆndings indicate that water-solubilized extracts of S. horneri have a direct inhibitory eŠect on bone resorption in tissue culture in vitro.
S. horneri extract has been found to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption in vitro. [111] [112] [113] Those active components are found to be present in S. horneri obtained from various coasts in Japan (Shimoda and Iwate) and China. 114) The active component of S. horneri extract in stimulating bone calciˆcation is found to be near MW 1000. The eŠect of this component disappeared with heat treatment of the extract. Meanwhile, the active component of S. horneri extract in inhibiting osteoclastic cell formation was more than MW 50000. This component was stable under heat treatment. It is speculated that the active component in stimulating bone calciˆcation is a peptide or chemical, and that the compound in inhibiting bone resorption is a polysaccharide. These active components obtained from the coasts of Iwate or China showed an identical molecular weight. Thus the active components are found in S. horneri extracts obtained from diŠerent coasts. Interestingly, the two active components are present in S. horneri extract.
The anabolic eŠects of S. horneri extract on bone components in the femoral tissues of young and aged rats in vivo was demonstrated. 115) Calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues of young male (4-week-old) rats was signiˆcantly increased with the administration of S. horneri extract (2.5, 5, and 10 mg/100 g) for 7 days. Moreover, these bone components in the femoral-diaphyseal and -metaphyseal tissues of aged female (50-week-old) rats were signiˆcantly increased by the administration of S. horneri extract (10 mg/100 g) for 14 days, suggesting a preventive eŠect on bone loss with increasing age.
Wheter the intake of S. horneri extract has a preventive eŠect on bone loss in a pathophysiologic state was examined. 116) Diabetes has been shown to induce bone loss. 117, 118) The oral administration of S. horneri extract to STZ-diabetic rats was found to have a preventive eŠect on bone loss with diabetes in vivo. 116) Thisˆnding suggests that the dietary intake of S. horneri extract has a preventive eŠect on bone loss in the pathophysiologic state. When the femoral tissues obtained from STZ-diabetic rats were cultured in medium containing S. horneri extract solution, the femoral calcium content and alkaline phosphatase activity were signiˆcantly increased in vitro. Alkaline phosphatase is related to bone calciˆcation. S. horneri extract has been shown to stimulate bone formation and to inhibit bone resorption in vitro. Presumably, the preventive eŠect of S. horneri extract administration on diabetes-induced bone loss is related to a direct action of the active component of S. horneri extract.
Interestingly, the oral administration of S. horneri extract to STZ-diabetic rats was found to have a signiˆcant preventive eŠect on the decrease in body weight and the increase in serum glucose and triglyceride levels induced in the diabetic state. 114) This is a novelˆnding. The intake of S. horneri extract has a partial restorative eŠect on serum biochemicalˆnding with diabetes in vivo. Whether the active component of S. horneri extract in preventing bone loss induced with diabetes is identical to the component that prevents an elevation of serum glucose and triglyceride levels with diabetes is unknown. Thus the intake of S. horneri extract has been demonstrated to have preventive eŠects on bone loss, hyperglycemia, and hyperlipidemia in STZ-diabetic rats.
EŠects of Bee Pollen Extract on Bone Metabolism Bee pollen is generally used as a nutrient factor. The role of bee pollen in the prevention of bone loss with increasing age has not yet been clariˆed. Bee pollen extract was found to have anabolic eŠects on bone components in the femoral-diaphyseal and -metaphyseal tissues of rats in vitro and in vivo. 119) Of various bee pollens, the water-solubilized extract obtained from Cistus ladaniferus had a marked eŠect in increasing the bone calcium content. The ethanolsolubilized extract of bee pollen also signiˆcantly increased the bone calcium content. However, the eŠects of the water-solubilized extract in increasing the bone calcium content were greater than those of the ethanol-solubilized extract. The active component in bee pollen was thus present in water-solubilized extract. Culture with the extract obtained from the pollen of C. ladaniferus caused a signiˆcant increase in alkaline phosphatase activity and DNA content in the femoral-diaphyseal and -metaphyseal tissues in vitro. These increases were completely inhibited in the presence of cycloheximide, suggesting that its stimulatory eŠect results from newly synthesized protein components.
The water-solubilized extract of bee pollen obtained from C. ladaniferus has been shown to have inhibitory eŠects on bone resorption in femoral tissues and osteoclast-like cell formation in bone marrow cell culture in vitro. 120) Bee pollen extract has stimulatory eŠects on bone formation and inhibitory eŠects on bone resorption in vitro.
The eŠects of bee pollen, propolis, and royal jelly extracts were compared. The eŠects of water-solubi-lized extract or ethanol-solubilized extract obtained from propolis on bone calcium content in vitro were prepared. 119) The water-solubilized extract (100 mg/ ml of medium) caused a signiˆcant increase in bone calcium content. The ethanol-solubilized extract (10, 50, or 100 mg/ml) did not have signiˆcant eŠects on bone calcium content. Meanwhile, royal jelly (50 or 100 mg/ml) signiˆcantly increased calcium content in rat femoral tissues in vitro. 121) However, culture with royal jelly (1-100 mg/ml) did not have a suppressive eŠect on PTH-induced increase in osteoclast-like cell formation in bone marrow culture in vitro. 121) Among bee-related factors, bee pollen extract has a potent anabolic eŠect on bone calciˆcation. The identiˆcation of the active component in bee pollen extracts is in progress.
The oral administration of the water-solubilized extract obtained from the pollen of C. ladaniferus to rats caused a signiˆcant increase in calcium content in the femoral-diaphyseal and -metaphyseal tissues, indicating that the extract exerts anabolic eŠects on bone components in vivo. 119) It is speculated that the active component in the water-solubilized extract obtained from the pollen of C. ladaniferus is transported in the intestine, and acts on osteoblastic cells in bone tissues. If the active component is transported in the intestine, it may not be a high molecular-weight compound. The active component in bee pollen extract is found in the fraction of less than MW 1000. 122) EŠects of Phytocomponent p-Hydroxycinnamic Acid on Bone Metabolism
Cinnamic acid is present in many plant and fruits. p-Hydroxycinnamic acid is an intermediate-metabolic substance in plant and fruits and it is synthesized from tyrosine. The eŠect of cinnamic acid or its related compounds on bone metabolism has not yet been clariˆed.
Rat femoral-diaphyseal or -metaphyseal tissues were cultured for 48 h in medium containing cinnamic acid, p-hydroxycinnamic acid (HCA) ferulic acid, caŠeic acid or 3,4-dimethoxycinnamic acid (DCA) in vitro. 123) Culture with HCA (10 -5 or 10 -4 M) caused a signiˆcant increase in calcium content in the diaphyseal and metaphyseal tissues. Such an eŠect was not observed in the presence of cinnamic acid or other compounds at the concentration of 10 Alkaline phosphatase activity and DNA content in the diaphyseal or metaphyseal tissues was signiˆcant-ly increased in the presence of HCA (10 -5 or 10 -4 M). The eŠects of HCA (10 -4 M) in increasing calcium content, alkaline phosphatase activity, and DNA content in the diaphyseal or metaphyseal tissues were completely prevented in the presence of cycloheximide (10 -6 M), an inhibitor of protein synthesis. HCA was found to have anabolic eŠects on bone components.
Culture with PTH caused a signiˆcant decrease in calcium content and a corresponding elevation in medium glucose consumption, lactic acid production, or TRACP activity in the diaphyseal or metaphyseal tissues. These alterations were completely prevented in the presence of HCA (10 -5 or 10 -4 M). Thus HCA was found to have inhibitory eŠects on bone resorption in tissue culture in vitro. 123) The anabolic eŠects of phytocomponent HCA on the bone of rats in vivo were determined. 124) Rats were orally administered HCA 1, 2, or 5 mg/100 g body weight once daily for 7 days. The administration of HCA did not cause a signiˆcant change in body weight or serum calcium and inorganic phosphorus levels. Calcium content, alkaline phosphatase activity, and DNA content in the diaphyseal and metaphyseal tissues were signiˆcantly increased with the administration of HCA 2 or 5 mg/100 g. Diaphyseal calcium and metaphyseal DNA contents were signiˆcantly increased with the dose of HCA 1 mg/100 g. The activity of TRACP, which is a marker enzyme of osteoclastic bone resorption, was signiˆcantly decreased with the administration of HCA 1, 2, or 5 mg/100 g. The administration of HCA was found to have anabolic eŠects on bone calciˆcation in the femoral tissues of rats in vivo.
Phycomponent HCA may have a preventive eŠect on bone loss with increasing age. Further study is in progress to determine a role in therapy of osteoporosis.
PROSPECTS
Bone loss with aging induces osteoporosis, and a decrease in bone mass leads to bone fracture. Bone loss may be due to decreased bone formation and increased bone resorption. Pharmacologic and food factors are needed to prevent bone loss with increasing age. Chemical factors in food and plants may help to prevent bone loss with aging.
Recent studies in our laboratory have shown that iso‰avones (including genistein and daidzein), which are contained in soybeans, have a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on osteoclastic bone resorption, thereby increasing bone mass. Also, menaquinone-7, an analogue of vitamin K 2 abundant in fermented soybeans, has been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption. Of various carotenoids (including lutein, lycopone, and b-carotene), b-cryptoxanthin, which is abundant in Satsuma mandarin (C. unchiu MARC), has a stimulatory eŠect on osteoblastic bone formation and an inhibitory eŠect on osteoclastic bone resorption. The supplementation of iso‰avone, menaquinone-7, and b-cryptoxanthin has a preventive eŠect on bone loss induced by OVX in rats, which is an animal model of osteoporosis. These factors have been demonstrated to have anabolic eŠects on bone metabolism in humans. Food chemical factors play a role in bone health and may be important in the prevention of bone loss with increasing age.
Among other food and plants, factors that have an anabolic eŠect on bone metabolism are found in extracts obtained from wasabi leafstalk (W. japonica MATSUM), marine alga S. horneri, and bee pollen from C. ladaniferus. Phytocomponent HCA, which is present in many plants and fruit, has also been shown to have an anabolic eŠect on bone metabolism.
Drugs used clinically in the treatment and therapy of osteoporosis are mainly based on the action of osteoclastic bone resorption. A clinical compound that stimulates bone formation is under development. As described in this review, chemical factors that can stimulate bone formation are found in various food and plants. These factors may be usefulness in the prevention and therapy of osteoporosis. It is expected that studies of the chemical structure-related activity of biofactors from food and plants will lead to the development of new drugs that stimulate bone formation and inhibit bone resorption.
The supplemental intake of food and plant factors that increase bone mass may play a role in maintaining bone health and in prevention of bone loss with increasing age. Further studies are needed to identify food and plant factors that have an anabolic eŠect on bone metabolism.
